

Introduction

Many clinical studies report summary statistics such as the median, quartiles, and range in boxplots, rather than providing sample means and standard deviations, which are crucial for metaanalyses.

To bridge this gap, we propose a novel Bayesian approach that utilizes the joint distribution of order statistics and weakly informative priors to estimate the mean and standard deviation while also quantifying uncertainty. Ultimately, our method enhances the reliability of quantitative synthesis in clinical research.

Problem Setup

n = sample size S_i = Scenario *i* a = the minimum value q_1 = the first quartile $S_0 = \{\bar{x}, s; n\}$ m = the median $S_1 = \{a, m, b; n\}$ q_3 = the third quartile $S_2 = \{q_1, m, q_3; n\}$ b = the maximum value $S_3 = \{a, q_1, m, q_3, b; n\}$

Let $x_1, x_2, ..., x_n$ be a random sample of size *n* from the normal distribution N(μ, σ^2), and $X_{(1)} \leq$ $X_{(2)} \leq \cdots \leq X_{(n)}$ be the ordered statistics of x_1, x_2, \dots, x_n . For simplicity, let n = 4q + 1, with *q* being positive integer.



Figure 1 Illustration of the data structure for the case n=4q+1 across all three scenarios.

 $p(\mu,\sigma^2 \mid$



We

Recovering Mean and Standard Deviation from Boxplot Data: A Novel Bayesian Approach

Wenqisi (Lydia) Pan¹, Zeyu Lu¹, Lin Xu², Xinlei Wang¹ The University of Texas at Arlington, Arlington, Texas.¹ University of Texas Southwestern Medical Center, Dallas, Texas.²

Method

$S_1 = \{a, m, b; n\}$

$$\begin{split} X) &\propto p(X \mid \mu, \sigma^2) \cdot \pi(\mu) \cdot \pi(\sigma^2) \\ &\propto N(X_{(1)} \mid \mu, \sigma^2) \cdot N(X_{(2q+1)} \mid \mu, \sigma^2) \cdot N(X_{(4q+1)} \mid \mu, \sigma^2) \\ &\cdot \left[\Phi\left(\frac{X_{(2q+1)} - \mu}{\sigma}\right) - \Phi\left(\frac{X_{(1)} - \mu}{\sigma}\right) \right]^{2q-1} \\ &\cdot \left[\Phi\left(\frac{X_{(4q+1)} - \mu}{\sigma}\right) - \Phi\left(\frac{X_{(2q+1)} - \mu}{\sigma}\right) \right]^{2q-1} \\ &\cdot \pi(\mu) \cdot \pi(\sigma^2) \end{split}$$

$S_2 = \{q_1, m, q_3; n\}$

 $p(\mu, \sigma^2 \mid X) \propto p(X \mid \mu, \sigma^2) \cdot \pi(\mu) \cdot \pi(\sigma^2)$

$$\begin{split} &\propto N(X_{(q+1)} \mid \mu, \sigma^2) \cdot N(X_{(2q+1)} \mid \mu, \sigma^2) \cdot N(X_{(3q+1)} \mid \mu, \sigma^2) \\ &\cdot \left[\Phi\left(\frac{X_{(q+1)} - \mu}{\sigma}\right) \right]^q \\ &\cdot \left[\Phi\left(\frac{X_{(2q+1)} - \mu}{\sigma}\right) - \Phi\left(\frac{X_{(q+1)} - \mu}{\sigma}\right) \right]^{q-1} \\ &\cdot \left[\Phi\left(\frac{X_{(3q+1)} - \mu}{\sigma}\right) - \Phi\left(\frac{X_{(2q+1)} - \mu}{\sigma}\right) \right]^{q-1} \\ &\cdot \left[1 - \Phi\left(\frac{X_{(3q+1)} - \mu}{\sigma}\right) \right]^q \\ &\cdot \pi(\mu) \cdot \pi(\sigma^2) \end{split}$$

$S_3 = \{a, q_1, m, q_3, b; n\}$

$$\begin{split} \sigma^{2} \mid X) &\propto p(X \mid \mu, \sigma^{2}) \cdot \pi(\mu) \cdot \pi(\sigma^{2}) \\ &\propto N(X_{(1)} \mid \mu, \sigma^{2}) \cdot N(X_{(q+1)} \mid \mu, \sigma^{2}) \cdot N(X_{(2q+1)} \mid \mu, \sigma^{2}) \\ &\cdot N(X_{(3q+1)} \mid \mu, \sigma^{2}) \cdot N(X_{(4q+1)} \mid \mu, \sigma^{2}) \\ &\cdot \left[\Phi\left(\frac{X_{(q+1)} - \mu}{\sigma}\right) - \Phi\left(\frac{X_{(1)} - \mu}{\sigma}\right) \right]^{q-1} \\ &\cdot \left[\Phi\left(\frac{X_{(2q+1)} - \mu}{\sigma}\right) - \Phi\left(\frac{X_{(q+1)} - \mu}{\sigma}\right) \right]^{q-1} \\ &\cdot \left[\Phi\left(\frac{X_{(3q+1)} - \mu}{\sigma}\right) - \Phi\left(\frac{X_{(2q+1)} - \mu}{\sigma}\right) \right]^{q-1} \\ &\cdot \left[\Phi\left(\frac{X_{(4q+1)} - \mu}{\sigma}\right) - \Phi\left(\frac{X_{(3q+1)} - \mu}{\sigma}\right) \right]^{q-1} \\ &\cdot \left[\Phi\left(\frac{X_{(4q+1)} - \mu}{\sigma}\right) - \Phi\left(\frac{X_{(3q+1)} - \mu}{\sigma}\right) \right]^{q-1} \end{split}$$

specify the prior of
$$\mu$$
 and σ^2 as:
 $\pi(\mu) \propto I(L_{\mu} \leq \mu \leq U_{\mu})$
 $\pi(\sigma^2) \propto (\sigma^2)^{-\alpha-1} e^{-\frac{\beta}{\sigma^2}}$

The lower and upper bound was set for μ to a safe range and $\alpha = \beta = 0.01$ for σ^2 . With 2-dimensional grid approximation, we can get our estimates for μ and σ , denoted as \hat{x} and \hat{s} .

Results









References

1.	Wan, Xia
2.	Luo, D., V
	research,
3.	Shi, Jiand
4.	McGrath,
	from com



Figure 2 Relative Mean Square Error of the sample mean and sample standard deviation estimation for normal data. $\operatorname{RMSE}(\widehat{x}) = \frac{\frac{1}{T}\sum_{t=1}^{T}(\widehat{x}-\mu)^2}{\frac{1}{T}\sum_{t=1}^{T}(\overline{x}-\mu)^2}, \operatorname{RMSE}(\widehat{s}) = \frac{1}{T}\sum_{t=1}^{T}(\widehat{x}-\mu)^2}{\frac{1}{T}\sum_{t=1}^{T}(\widehat{x}-\mu)^2}, \operatorname{RMSE}(\widehat{s}) = \frac{1}{T}\sum_{t=1}^{T}(\widehat{s}-\mu)^2}{\frac{1}{T}\sum_{t=1}^{T}(\widehat{s}-\mu)^2}, \operatorname{RMSE}(\widehat{s}-\mu)^2}{\frac{1}{T}\sum_{t=1}^{T}(\widehat{s}-\mu)^2}{\frac{1}{T}\sum_{t=1}^{T}(\widehat{s}-\mu)^2}, \operatorname{RMSE}(\widehat{s}-\mu)^2}{\frac{1}{T}\sum_{t=1}^{T}(\widehat{s}-\mu)^2}{\frac{1}{T}\sum_{t=1}$ $=\frac{\frac{1}{T}\sum_{t=1}^{T}(\hat{s}-\sigma)^{2}}{1-\tau}, smaller$ *RMSE value indicates better performance.*

Figure 3 Relative Mean Square Error of the sample mean and sample standard deviation estimation for skewed data (Robustness Testing).

> ang, et al. "Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range." BMC medical research methodology 14 (2014): 1-13. Wan, X., Liu, J., & Tong, T. (2018). Optimally estimating the sample mean from the sample size, median, mid-range, and/or mid-quartile range. Statistical methods in medical , 27(6), 1785-1805.

long, et al. "Optimally estimating the sample standard deviation from the five-number summary." Research synthesis methods 11.5 (2020): 641-654. , S., Zhao, X., Steele, R., Thombs, B. D., Benedetti, A., & DEPRESsion Screening Data (DEPRESSD) Collaboration. (2020). Estimating the sample mean and standard deviation monly reported quantiles in meta-analysis. Statistical methods in medical research, 29(9), 2520-2537. 5. Cai, Siyu, Jie Zhou, and Jianxin Pan. "Estimating the sample mean and standard deviation from order statistics and sample size in meta-analysis." Statistical methods in medical research 30.12 (2021): 2701-2719.

6. Yang, B., Huang, X., Gao, H., Leung, N. H., Tsang, T. K., & Cowling, B. J. (2022). Immunogenicity, efficacy, and safety of SARS-CoV-2 vaccine dose fractionation: a systematic review and meta-analysis. BMC medicine, 20(1), 409.

Conclusion

Estimation Accuracy (RMSE)

- ✓ Our method remains competitive among top methods across all scenarios (S1–S3) ✓ Shows consistently low RMSE, especially for
- estimating σ

Robustness

- ✓ Stable performance across small sample sizes, skewed or heavy-tailed distributions, and the presence of outliers
- ✓ Robust estimation of σ across all scenarios and competitive performance for μ

Uncertainty Quantification

- \checkmark Provides credible intervals for both μ and σ , which is not available in any other methods
- ✓ Coverage rate consistently greater than 0.95 across all scenarios, ensuring reliable interval estimates — critical for clinical data applications

Bayesian Framework

- Bayesian approach enables the integration of new clinical datasets as priors
- Posterior updating without re-running all simulations
- Efficient incorporation of historical evidence

Future Work

- > Extend to varying **treatment effect** measures in meta-analyses
- > Develop customized methods for the other skewed distributions
- > Enhance real-world applicability when data deviate from normality